Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering and developing therapeutics for neurological, endocrine, and psychiatric disorders in the United States. Its primary products include INGREZZA, a treatment for tardive dyskinesia, and ORILISSA, used for endometriosis. The company is advancing several clinical candidates, including elagolix, which targets uterine fibroids, and opicapone, an adjunct therapy for Parkinson’s disease. Additionally, Neurocrine is developing innovative therapies such as NBI-74788 for congenital adrenal hyperplasia and NBIb-1817, a gene replacement therapy for Parkinson’s disease. The company’s research also encompasses treatments for various conditions, including anxiety, depression, and epilepsy. Neurocrine has established collaborations with multiple pharmaceutical companies to enhance its research and development capabilities. Founded in 1992, the company is headquartered in San Diego, California.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Burnaby, Canada, focused on developing innovative therapeutics for neurological disorders. The company's clinical pipeline includes several product candidates targeting epilepsy, such as XEN496 and XEN1101, both Kv7 potassium channel modulators currently in Phase II trials, and XEN901, a selective Nav1.6 sodium channel inhibitor in Phase I trials. Additionally, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase I trials. Xenon utilizes a proprietary discovery platform, known as Extreme Genetics, to identify genetic insights from families with severe phenotypes, enabling the development of novel medicines for both orphan and more common diseases. The company has established a collaboration with Neurocrine Biosciences to advance first-in-class treatments for epilepsy, highlighting its commitment to addressing unmet medical needs in the field of neurology.
Northwest Neurologic
Acquisition in 1998
Northwest Neurologic Inc. (NNL) identifies and discovers neuroendocrine pathways to control obesity, stroke, depression, and other medical problems.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.